

Lumakras (sotorasib)
Effective 04/01/2022

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input checked="" type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Lumakras is indicated for the treatment of KRAS G12C-mutated locally advanced or metastatic non–small cell lung cancer (NSCLC), as determined by an approved test, in adults who have received at least 1 prior systemic therapy.

Coverage Guidelines

Authorization may be granted for members new to the plan who are currently receiving treatment with Lumakras, excluding when the product is obtained as samples or via manufacturer’s patient assistance program
OR

Approval of Lumkras will be granted if the member meets all following criteria and documentation has been submitted:

1. The member has a diagnosis of advanced or metastatic non-small cell lung cancer (NSCLC)
2. Cancer has KRAS G12C mutation
3. The prescriber is an oncologist
4. The member has had inadequate response or adverse reaction to at least one prior systemic therapy or contraindication to the use of systemic therapy

Continuation of Therapy

Reauthorizations requires physician documentation of continuation of therapy and positive response to therapy.

Limitations

1. Initial approvals and Reauthorizations will be granted for 12 months.
2. The following quantity limits apply:

Lumakras 120mg	240 tablets per 30 days
----------------	-------------------------

References

1. Lumakras (sotorasib) [prescribing information]. Thousand Oaks, CA: Amgen Inc; May 2021.

Review History

03/16/2022 - Reviewed and Created at Jan P&T. Effective 04/01/2022.

